Viral infections after the use of rituximab and fungal infections after the use of regimens containing BTK inhibitors have been reported in the literature.[5,6] There are no reports of immunodeficiency leading to Strongyloides stercoralis infection after combined targeted therapy with rituximab and BTK inhibitors. The gene discussed is BTK; the disease is fungal infectious disease.